---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001880"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:01:05.061413+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma appoints Christopher Cooper interim CEO; founder Dritschilio CSO & Chairman

## Summary
- Christopher Cooper appointed interim CEO effective March 30, 2025.
- Founder Dr. Anatoly Dritschilio becomes Chief Scientific Officer, remains Chairman of the Board.
- Amended employment agreement: 3-year term, $274,000/year base salary, 12-month severance.
- Dritschilio tasked with completing Phase 2 Ropidoxuridine glioblastoma trial by 2026, initiating Phase 3 by 2028.
- Restructuring aims to add expertise in business and capital markets activities.

## SEC filing metadata
- accession: 0001641172-25-001880
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000164117225001880/0001641172-25-001880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000164117225001880/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001880
- JSON: https://secwatch.observer/filing/0001641172-25-001880.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001880.txt

## Source-grounded claims
- claim_id: acbb6d64db
  claim: Christopher Cooper was appointed as interim Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..
  evidence_excerpt: Effective March 30, 2025, the Company’s Board of Directors approved the appointment of Christopher Cooper to the position of interim Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000164117225001880/0001641172-25-001880-index.htm
- claim_id: b63360ae84
  claim: Anatoly Dritschilo was appointed as Chief Scientific Officer at Shuttle Pharmaceuticals Holdings, Inc..
  evidence_excerpt: Anatoly Dritschilo, M.D., to the position of Chief Scientific Officer. Dr. Dritschilo will also continue to hold the position of Chairman of the Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000164117225001880/0001641172-25-001880-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.